Diaceutics PLC represents a strong commitment to revolutionizing patient testing in the global diagnostic industry. The company's corporate philosophy is rooted in driving better patient outcomes by improving diagnostic testing for precision medicine. With a focus on leveraging data analytics and deep industry knowledge, Diaceutics PLC aims to bridge the gap between diagnostic testing and targeted therapies. By partnering with pharmaceutical companies, laboratories, and healthcare providers, Diaceutics PLC strives to enable faster and more accurate testing to ensure patients receive the right treatment at the right time. Through innovation, collaboration, and patient-centricity, Diaceutics PLC is dedicated to empowering precision medicine and transforming healthcare.

Diaceutics PLC is primarily present in multiple countries and regions worldwide. The company operates globally, with a strong presence in the United States, Europe, and key Asian markets. This includes countries such as the United Kingdom, Germany, France, Spain, Italy, China, Japan, and Australia, among others. With its expansive reach, Diaceutics PLC caters to healthcare providers, pharmaceutical companies, and diagnostic laboratories in various regions, enabling better personalized medicine and improving patient outcomes.

Diaceutics PLC, a leading diagnostic data analytics and implementation services provider, has achieved several significant milestones. Firstly, the company successfully listed on the AIM market of the London Stock Exchange in March 2019, marking a major achievement in terms of financial market recognition. Additionally, Diaceutics has experienced substantial growth, expanding its global reach and establishing strategic partnerships with renowned pharmaceutical companies. Moreover, the company has received multiple awards and recognition for its innovative and impactful contributions to precision medicine. Diaceutics PLC's remarkable achievements are a testament to its commitment to revolutionizing the way healthcare providers utilize diagnostic testing, ultimately improving patient outcomes.

Diaceutics PLC is a leading data analytics and implementation services provider in the personalized medicine industry. Founded in 2005, the company has grown steadily and garnered a strong reputation for its expertise in diagnostic testing. It enables pharmaceutical companies, laboratories, and healthcare providers to optimize the use of targeted therapies for patients by leveraging advanced data analytics. Diaceutics PLC's robust platform helps bridge the gap between diagnostic testing and personalized medicine, significantly improving patient outcomes. With its deep industry knowledge and proprietary data-driven solutions, the company has become a trusted partner for life science companies globally, unlocking the potential of precision medicine.

The main competitors of Diaceutics PLC in the market include companies such as LabCorp, QIAGEN, Foundation Medicine, and Genomic Health.

Diaceutics PLC is primarily active in the healthcare and pharmaceutical industries. As a leading diagnostic commercialization company, Diaceutics specializes in helping pharmaceutical companies and laboratories improve patient outcomes through the delivery of precision medicine. With their extensive expertise in data analytics and laboratory network management, Diaceutics empowers healthcare providers to effectively integrate diagnostic testing into patient treatment pathways, thereby enhancing personalized medicine.

The business model of Diaceutics PLC focuses on providing personalized diagnostics solutions and services to the pharmaceutical industry. Diaceutics helps pharmaceutical companies and laboratories optimize their diagnostic testing processes, ensuring patients receive accurate and timely test results. By harnessing real-world data and leveraging their expertise in diagnostic commercialization, the company enables precision medicine and improves patient outcomes. With a comprehensive approach that includes strategic consulting, data analytics, and software solutions, Diaceutics aims to bridge the gap between diagnostic testing and the delivery of targeted therapies.

Diaceutics P/E suhe on −59,24.

Diaceutics KUV on 3,75.

AlleAktien kvaliteediskoor ettevõttele Diaceutics on 3/10.

oodatud Diaceutics käive on 29,87 mln. GBP.

oodatud Diaceutics kasum on −1,89 mln. GBP.

Diaceutics PLC is an international company specializing in improving the diagnostics and care of cancer patients. The company's business model is based on the use of data analysis to understand the connections between diagnostics, therapy, and patient outcomes in order to optimize cancer treatment.

Diaceutics maksab dividendi 0 GBP, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Diaceutics jaoks arvutada või ettevõte ei maksa dividende välja.

Diaceutics ISIN on GB00BJQTGV64.

Diaceutics WKN on A2PF80.

Diaceutics tähis on DXRX.L.

Viimase 12 kuu jooksul maksis Diaceutics dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Diaceutics tõenäoliselt dividendi summas 0 GBP.

Diaceutics praegune dividenditootlus on .

Diaceutics maksab kvartaalset dividendi. See makstakse välja kuudel .

Diaceutics maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 GBP. See vastab dividenditootlusele 0 %.

Diaceutics on liigitatud sektorisse 'Tervis'.

Viimase Diaceutics dividendide saamiseks 20.9.2024 suuruses 0 GBP pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 20.9.2024.

Viimane dividendimakse toimus 20.9.2024.

Aastal 2023 maksis Diaceutics 0 GBP dividende.

Diaceutics dividendid makstakse välja GBP.